Arrazubi, VirginiaGoñi Irigoyen, SaioaGonzález Borja, IranzuHernández García, IreneArasanz Esteban, HugoPérez Sanz, JairoBocanegra Gondán, Ana IsabelKochan, GrazynaEscors Murugarren, DavidRuiz de Azúa, YeraniElizalde, Jesús MaríaViúdez, AntonioVera García, Ruth2024-04-292023Arrazubi, V., Goñi, S., González-Borja, I., Hernandez-Garcia, I., Arasanz, H., Pérez-Sanz, J., Bocanegra, A. I., Kochan, G., Escors, D., Ruiz de Azúa, Y., Elizalde, J. M., Viúdez, A., Vera, R. (2023) Circulating low density neutrophils are associated with resistance to anti-PD1 immunotherapy in squamous head and neck cancer. Head & Neck: Journal for the Sciences and Specialities of the Head and Neck, 45(12), 3075-3085. https://doi.org/10.1002/hed.27536.1043-307410.1002/hed.27536https://academica-e.unavarra.es/handle/2454/48042Background: Identification of predictive biomarkers to Immune checkpoint inhibitors (ICIs) in head and neck cancer (HNSCC) is an unmet need. Methods: This was a prospective observational study including 25 patients with HNSCC treated with immunotherapy or chemotherapy after a prior platinum-based regimen. Low density neutrophils (LDNs) and serum markers were analyzed. Results: In the immunotherapy cohort, patients with high LDN levels had a shorter progression free survival (PFS) (1.8 months vs. 10.9 months; *p = 0.034). Also, progressors showed higher percentage of LDNs compared to non-progressors although significance was not reached (mean 20.68% vs. 4.095%, p = 0.0875). These findings were not replicated in patients treated with chemotherapy. High levels of interleukin-7 (IL7) were correlated with a significantly longer overall survival (OS) (13.47 months 3.51 vs. months, *p = 0.013). Conclusions: High baseline circulating LDNs and low IL7 could identify a subset of patients intrinsically refractory to ICIs as monotherapy in HNSCC.application/pdfeng© 2023 Wiley Periodicals LLC.BiomarkerHead and neck cancer (HNC)ImmunotherapyLow density neutrophils (LDN)PredictiveCirculating low density neutrophils are associated with resistance to anti-PD1 immunotherapy in squamous head and neck cancerinfo:eu-repo/semantics/article2024-04-29info:eu-repo/semantics/openAccess